^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Truxima (rituximab-abbs)

    i
    Other names: CT-P10, TL011, TL 011
    Company:
    Celltrion, Indukern, Mundipharma, Nippon Kayaku, Teva
    Drug class:
    CD20 inhibitor
    Related drugs:
    1d
    The CARDIOPROTECT Trial (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Beth Israel Deaconess Medical Center
    New P2 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • Truxima (rituximab-abbs) • Myocet (non-pegylated liposomal doxorubicin) • Polivy (polatuzumab vedotin-piiq) • dexrazoxane
    2d
    AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • Columvi (glofitamab-gxbm) • Mabtas (rituximab biosimilar)
    7d
    RIGA: Evaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA Vasculitis (clinicaltrials.gov)
    P3, N=75, Completed, Hopital Foch | Active, not recruiting --> Completed | Trial primary completion date: Jul 2025 --> Jan 2026
    Trial completion • Trial primary completion date
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs)
    7d
    Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial (clinicaltrials.gov)
    P3, N=102, Not yet recruiting, SWOG Cancer Research Network | Initiation date: May 2026 --> Aug 2026
    Trial initiation date
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • Jaypirca (pirtobrutinib) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Mabtas (rituximab biosimilar)
    7d
    NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • gemcitabine • Rituxan (rituximab) • oxaliplatin • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    8d
    APHP240796: PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANCA repositivation in patients with granulomatosis with polyangiitis and microscopic polyangiitis (2025-522049-23-00)
    P4, N=70, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P4 trial
    |
    Rituxan (rituximab) • prednisone • Truxima (rituximab-abbs)
    8d
    A clinical trial of MK-1045 and rituximab in people with follicular lymphoma (MK-1045-007) (2025-522777-10-00)
    P2/3, N=2, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • Truxima (rituximab-abbs) • Actemra IV (tocilizumab)
    10d
    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) (clinicaltrials.gov)
    P2/3, N=960, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD)
    15d
    ICP-CL-00128: A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-na?ve mantle cell lymphoma (2025-524241-27-00)
    P2/3, N=40, Not yet recruiting, Innocare Pharma Inc.
    New P2/3 trial
    |
    CCND1 (Cyclin D1)
    |
    Rituxan (rituximab) • Inokai (orelabrutinib) • bendamustine • Truxima (rituximab-abbs)
    22d
    M22-128: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2024-510965-41-00)
    P2/3, N=116, Active, not recruiting, AbbVie Deutschland GmbH & Co. KG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    gemcitabine • Rituxan (rituximab) • lenalidomide • oxaliplatin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs)
    1m
    ONO-4059-17: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) (2025-523389-26-00)
    P2/3, N=6, Not yet recruiting, Deciphera Pharmaceuticals Inc.
    New P2/3 trial
    |
    Rituxan (rituximab) • temozolomide • Truxima (rituximab-abbs) • Velexbru (tirabrutinib)
    1m
    Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)